TYRA

Rating neutralAI Memo

Tyra Biosciences

As of 2026-05-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

SURF302 initial three-month complete response data remains the nearest real valuation test • 2026-06-30

Expected move: +18%

Biggest risk

The bear case is that this remains a concentrated clinical story with modest evidence density, no newer company earnings release or analyst revision signal located in this T+3 follow-up, and valuation still depends heavily on binary 2026 readouts rather than operating fundamentals.

Invalidation

Break below $26 or thesis failure.

What would change my mind?

The bull case is that the latest confirmed company update still shows runway through at least 2027, added March 2026 financing further reduced near-term capital pressure, and the stock still has room versus the available median target of $48.25 if SURF302 or BEACH301 data de-risk dabogratinib [#PR-2026-03-02] [#8-K-2026-03-04].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-03

Base target

$39

p=47%

Bull target

$49

p=28%

Bear target

$26

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Latest company-confirmed financial update still centers on runway and milestone pacing
BEACH301 achondroplasia sentinel results are the next franchise-broadening readout
The bull case is that the latest confirmed company update still shows runway through at least 2027, added March 2026 financing further reduced near-term capital pressure, and the stock still has room versus the available median target of $48.25 if SURF302 or BEACH301 data de-risk dabogratinib [#PR-2026-03-02] [#8-K-2026-03-04].

BearKey bullets

Board strengthening from the April 17, 2026 director appointment is governance-positive but not thesis-changing without clinical execution follow-through [#8-K-2026-04-17].
Clinical concentration risk remains high because dabogratinib drives the core thesis across IR NMIBC, LG-UTUC and achondroplasia, so weak SURF302 or BEACH301 data could hit the equity disproportionately [#PR-2026-03-02].
Despite improved liquidity, Tyra still carries dilution and capital-allocation risk after agreeing on March 4, 2026 to sell 4.0 million shares for $126.0 million in gross proceeds [#8-K-2026-03-04].

WatchKey bullets

SURF302 initial three-month complete response data remains the nearest real valuation test

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $39 (p=47%)

Bull/Bear spread: +48% / -21%

Vs latest close: Bull +48% · Base +18% · Bear -21%

Scenario probabilities

Bull Target: $49 (p=28%)Base Target: $39 (p=47%)Bear Target: $26 (p=25%)

Commentary

Sentiment remains cautious-to-neutral. The deterministic score shows a meaningful thesis-change signal, but the practical evidence change is still mostly the March 2026 company update plus financing, not a fully digested new earnings packet. As of May 3, 2026, we did not confirm a fresher company earnings release or a reliable set of delayed analyst revisions tied to the scheduled April 30, 2026 follow-up window, so missing post-print evidence should lower confidence rather than be read as positive. The monitoring focus stays on whether the mid-2026 SURF302 readout arrives on time and whether the stock can hold above the March financing price of $31.50 without new dilution concerns [#PR-2026-03-02] [#8-K-2026-03-04].

As of 2026-05-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Latest company-confirmed financial update still centers on runway and milestone pacing
BEACH301 achondroplasia sentinel results are the next franchise-broadening readout

Scenarios

Bull Target (Scenario probability)

$49 / p=28% prob

Base Target (Scenario probability)

$39 / p=47% prob

Bear Target (Scenario probability)

$26 / p=25% prob

Price $33 as of 2026-07-30

Nearest Scenario: Base (∆ 18%)

Targets vs latest close: Bull +48% · Base +18% · Bear -21%

Sentiment & Exposure

News Sentiment (30d)

0.12

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
SURF302 initial three-month complete response data remains the nearest real valuation test
Tyra said SURF302 in FGFR3-altered low-grade IR NMIBC remains expected to report initial three-month complete response data by the end of 1H 2026. For a low-coverage clinical biotech with limited fresh earnings follow-up, this remains the clearest near-dated proof point for whether dabogratinib can support a rerating beyond a monitoring thesis [#PR-2026-03-02].
Prob 70.00% • Move 21.00% • Priced-in 38.00%

Short-term Catalysts

Next few weeks

Latest company-confirmed financial update still centers on runway and milestone pacing
2026-05-03
As of May 3, 2026, we did not locate a newer company earnings release or 10-Q after the scheduled April 30, 2026 follow-up window, so the latest company-confirmed earnings update we found remains the March 2, 2026 release. That update said cash, cash equivalents and marketable securities were $256.0 million at December 31, 2025 and that runway should extend through at least 2027, while keeping the key 2026 clinical timing intact [#PR-2026-03-02].
Prob 85% • Move 4% • Priced-in 80%

Long-term Catalysts

Months to a year

BEACH301 achondroplasia sentinel results are the next franchise-broadening readout
2026-12-31
Management said BEACH301 interim safety sentinel results, including 6-month average height velocity and safety, remain expected in 2H 2026, after two of four dose levels were cleared with no safety events reported. Positive pediatric data would broaden the dabogratinib story beyond uro-oncology, while mixed data would reinforce single-asset concentration risk [#PR-2026-03-02].
Prob 65% • Move 24% • Priced-in 31%

Risks

Board strengthening from the April 17, 2026 director appointment is governance-positive but not thesis-changing without clinical execution follow-through [#8-K-2026-04-17].
Clinical concentration risk remains high because dabogratinib drives the core thesis across IR NMIBC, LG-UTUC and achondroplasia, so weak SURF302 or BEACH301 data could hit the equity disproportionately [#PR-2026-03-02].
Despite improved liquidity, Tyra still carries dilution and capital-allocation risk after agreeing on March 4, 2026 to sell 4.0 million shares for $126.0 million in gross proceeds [#8-K-2026-03-04].
Forward visibility is unusually thin for this T+3 earnings follow-up because we did not locate a newer company earnings release, 10-Q, or clear analyst revision set after the scheduled April 30, 2026 earnings date.

Peers

Symbol	Summary
EYPT	Clinical-stage biotech with similar market cap; useful as a readout-and-financing sensitivity comp, though not a direct FGFR3 peer.
QURE	Development-stage biotech of similar size; useful for thinking about platform credibility, cash runway, and binary data risk rather than indication overlap.
ATAI	Another similarly sized clinical-stage biotech where valuation is driven more by milestone timing and capital durability than current revenue; peer fit remains loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-03

AI Stock Memo: TYRA - Tyra Biosciences - RankAlpha